Natera Inc

NTRA

Equity

ISIN US6323071042 / Valor 28447012

NASDAQ (2024-09-16)

USD 129.67+2.50%

Natera Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Natera Inc. is a pioneering company in the healthcare sector, specializing in the development and commercialization of cell-free DNA (cfDNA) testing technologies. With a focus on oncology, women's health, and organ health, Natera strives to integrate personalized genetic testing and diagnostics into routine medical care. This approach is aimed at facilitating early and more precise interventions, ultimately contributing to improved health outcomes and extended life spans. The company's innovative solutions are designed to support patients and healthcare providers by offering critical insights into various health conditions and treatment responses, thereby enhancing the effectiveness of medical care. Through its commitment to advancing cfDNA testing, Natera plays a crucial role in the evolving landscape of personalized medicine.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Natera Inc. reported total revenues of $367.7 million for the first quarter of 2024, marking a significant increase of 52.1% compared to $241.8 million in the first quarter of 2023. This growth was primarily driven by a 53.4% increase in product revenues.

Test Volume

In the first quarter of 2024, Natera Inc. processed approximately 735,800 tests, a 17.5% increase from the 626,200 tests processed in the first quarter of 2023. This includes approximately 718,700 tests accessioned in its laboratory.

Gross Margin Improvement

Natera Inc. achieved a gross margin of 56.7% in the first quarter of 2024, compared to 38.7% in the same period of the previous year. The improvement in gross margin was attributed to higher revenues and ongoing efforts to reduce the cost of goods sold associated with tests processed.

Net Loss Reduction

For the first quarter of 2024, Natera Inc. reported a net loss of $67.6 million, or ($0.56) per diluted share, compared to a net loss of $136.9 million, or ($1.23) per diluted share, in the first quarter of 2023. This represents a significant reduction in net loss year-over-year.

Financial Outlook

Natera Inc. anticipates total revenue for 2024 to be in the range of $1.42 billion to $1.45 billion. The company also expects gross margins to be approximately 53% to 55% of revenues, with selling, general, and administrative costs projected to be between $700 million and $750 million.

Summarized from source with an LLMView Source

Key figures

152%1Y

7.73%3Y

284%5Y

Performance

44.6%1Y

64.6%3Y

66.7%5Y

Volatility